Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy

Launched by UMC UTRECHT · Feb 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with locally advanced pancreatic cancer, specifically looking at how an advanced type of radiation therapy called MR-guided radiotherapy (MRgRT) affects quality of life after patients have received standard chemotherapy. The trial will compare the results of patients who receive this MR-guided treatment along with their current care to those who only receive the standard treatment.

To participate in this trial, patients must have a confirmed diagnosis of pancreatic cancer that cannot be surgically removed and have undergone at least two months of specific chemotherapy regimens. They should not have signs of cancer spreading to other parts of the body and must be in good enough health to take part. Participants can expect to receive close monitoring throughout the study, and they will be contributing to important research that could help improve treatment options for others in the future. It’s important to know that this trial is not yet recruiting participants, so those interested will need to wait until it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathology proven pancreatic ductal adenocarcinoma (PDAC);
• • At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and/or gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish;
• • No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and/or frailty (unfit for surgery or chemotherapy) and/or no surgery based on patient's wish.
• • No evidence of distant metastatic disease progression, evaluated by CT Thorax / Abdomen / Pelvis and/or PET-CT scan;
• • Performance status WHO 0-2.
• Exclusion Criteria:
• • Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and/or radiotherapy departments
• • Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium
• • \<18 years old
• • Pregnancy